Changes in Membrane Cholesterol Differentially Influence Preferential and Non-preferential Signaling of the M1 and M3 Muscarinic Acetylcholine Receptors

Pavel Michal · Esam E. El-Fakahany · Vladimír Doležal

Received: 26 February 2014 / Revised: 19 April 2014 / Accepted: 3 May 2014 / Published online: 13 May 2014 © The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract We have found earlier that changes in membrane cholesterol content have distinct impact on signaling via the M1, M2, or M3 receptors expressed in CHO cells (CHO-M1 through CHO-M3). Now we investigated whether gradual changes in membrane cholesterol exerts differential effects on coupling of the M1 and M3 muscarinic receptors to preferential signaling pathways through $G_{q/11}$ and non-preferential $G_s$ G-proteins signaling. Changes in membrane cholesterol resulted in only marginal alterations of antagonist and agonist affinity of the M1 and M3 receptors, and did not influence precoupling of either subtype. Changes in membrane cholesterol did not influence parameters of carbachol-stimulated GTP-$\gamma^{35}S$ binding in CHO-M1 membranes while reduction as well as augmentation of membrane cholesterol lowered the efficacy but increased the potency of carbachol in CHO-M3 membranes. Gradual increase or decrease in membrane cholesterol concentration dependently attenuated agonist-induced inositolphosphates release while basal values in both cell lines increased. Similarly, membrane cholesterol manipulation modified basal and agonist-stimulated cAMP synthesis via $G_s$ in the same way in both cell lines. These results demonstrate that changes in membrane cholesterol concentration differentially impact preferential and non-preferential M1 and M3 receptor signaling. They point to the activated G-protein/effector protein interaction as the main site of action in alterations of M1 receptor-mediated stimulation of second messenger pathways. On the other hand, modifications in agonist-stimulated GTP-$\gamma^{35}S$ binding in CHO-M3 membranes indicate that in this case changes in ligand-activated receptor/G-protein interaction may also play a role.

Keywords Muscarinic receptors · Agonist binding · Cholesterol · G-Proteins · Signal transduction · cAMP synthesis

Introduction

Muscarinic receptors belong to the family of G-protein coupled receptors (GPCR) that are the most abundant and pharmaceutically targeted plasma membrane receptors [9, 22]. A common structural feature of GPCR is the extracellular N-terminus, seven membrane spanning domains, three extracellular, three intracellular loops, and intracellular C-terminus. Stimulation of GPCR leads to activation of specific G-proteins and their intracellular signaling pathways that play important regulatory roles in virtually all physiological functions. There are five subtypes of muscarinic receptors denoted as M1-M5 and encoded by five different genes [2–5, 31]. Individual muscarinic receptor subtypes share a high degree of homology in the transmembrane domains while the extracellular and intracellular loops are less conserved [13–15]. The intracellular C-terminus may form the fourth intracellular loop by means of a glycosyl anchor. The N-terminal part of the third intracellular loop represents the contact domain for interaction with G-proteins [12, 37]. Higher variability of this domain enables selectivity of interaction with different G-proteins.
The M1, M3, and M5 receptor subtypes preferentially activate Gq/11 G-protein intracellular signaling while the M2 and M4 subtypes prefer Gi/o G-proteins and activate their signaling pathways [20, 21]. However, it has been demonstrated that individual subtypes of muscarinic receptors can also interact with and activate non-preferential G-proteins [17, 19, 26, 27]. We have previously reported that experimental changes in membrane cholesterol concentration have various impacts on preferential second messenger signaling mediated by M1, M2, and M3 muscarinic receptors [28]. With respect to M1 and M3 receptors that prefer Gq/11 G-proteins we found that both increase and decrease in membrane cholesterol attenuates maximal effect (efficacy) of carbachol, a non-hydrolysable analog of the natural agonist acetylcholine, in stimulating cAMP synthesis while cholesterol depletion increased inhibition by carbachol without influencing its potency. In contrast, an increase in membrane cholesterol had no influence on preferential M2 receptor mediated inhibition of cAMP synthesis while cholesterol depletion increased inhibition by carbachol without influencing its potency.

However, as mentioned above, odd numbered muscarinic receptors expressed in CHO cells also activate Gs G-proteins. There can be mechanistic differences between Gq/11 and Gs G-protein activation of intracellular signaling pathways mediated by M1 or M3 receptors. While these receptors expressed in CHO cells precouple with Gq/11 and Gi/o G-proteins they do not precouple with Gs G-proteins [19]. In the present experiments we explored the influence of gradual changes in membrane cholesterol concentration on individual steps of signal transduction via M1 muscarinic receptors, including agonist binding, activation of G-proteins, and resulting stimulation of intracellular signaling pathways. Our aim was to reveal if there are differences between the effects of changing membrane cholesterol content on Gq/11 and Gs G-proteins signaling. To achieve this goal we determined binding parameters and functional response in CHO cells expressing the muscarinic M1 receptor (CHO-M1 cells) that prevails in the brain. For comparison we used CHO cells that express the M3 muscarinic receptor (CHO-M3). We demonstrate that changes in membrane cholesterol do not influence precoupling of either M1 or M3 receptors and result in only marginal alterations of antagonist and agonist affinity. Despite only slight alterations of receptor/G-protein interactions both increase and decrease in membrane cholesterol evoked significant modifications in cAMP synthesis.

**Methods**

**Cell Lines, Treatments, and Chemicals**

Experiments were performed essentially as described previously in Michal et al., 2009 [28]. Briefly, CHO cells stably transfected with the human genes of the muscarinic M1 and M3 receptor subtypes (CHO-M1 and CHO-M3 cells, respectively) were kindly supplied by Prof. Tom Bonner. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) with 10 % fetal calf serum and 0.005 % geneticin, and used for experiments three to 5 days after seeding. Cells were grown in 10 cm diameter Petri dishes for preparation of membranes or in 24-well or 48-well plates for assays on intact cells. Before experiment, cells for functional assays were loaded with 3H-adenine for 4 h or with 3H-myo-inositol for 4–12 h in DMEM. Then they were treated for 1 h at 37 °C in DMEM with indicated concentrations of methyl-β-cyclodextrin (MBCD; ranging from 1.25 to 10 mM) to deplete membrane cholesterol or with cholesterol-saturated methyl-β-cyclodextrin (Ch-MBCD; ranging from 0.25 to 4 mM) to increase membrane cholesterol. Cholesterol-modifying medium was washed off using DMEM and cells were used for measurements on intact attached cells or for preparation of membranes for binding assays.

Chemicals were obtained from Sigma (Prague, Czech Republic) unless indicated otherwise.

**Membrane Preparation**

Membranes were prepared as described by Jakubík et al. [17] from control cells or from cells that had been treated with cholesterol-modifying agents as described above.

**Saturation and Competition Binding Assays**

Binding characteristics of muscarinic receptors were determined in equilibrium binding experiments with the membrane-impermeable quaternary amine muscarinic antagonist [3H]-N-methylscopolamine (3H-NMS) (ARC, USA) as a tracer. Densities and affinities of muscarinic receptors were determined in saturation assays on intact attached cells or cell membranes as described [17, 18, 33].

Intact cells were incubated for 1 h at 37 °C in 0.5 ml of DMEM containing increasing concentrations of 3H-NMS ranging from 63 pM to 2.0 nM. Attached cells were then quickly washed with cold phosphate buffered saline to remove unbound ligand, dissolved in 1 M NaOH, and aliquots of these lysates were used for scintillation counting and protein determination. Membranes were suspended in binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM Na-HEPES, pH 7.4) and aliquots (5–20 μg of protein in a final volume 400 μl) in 96-well-plate were incubated for 1 h at 25 °C in the presence of 63 pM–2 nM 3H-NMS. Incubation was terminated by filtration through Whatman GF/B glass fiber filters (Whatman) using a Brandel harvester (Brandel, USA). Filters were dried and counted in scintillation cocktail Rotiszint (Carl Roth, Germany) in
Wallac Microbeta scintillation counter (Wallac, Finland). Non-specific binding was determined in the presence of 10 µM atropine.

Binding characteristics of the muscarinic agonist carbachol were determined analogically in competition experiments with 1 nM [3H]-NMS as a tracer.

Functional Assays

IPs accumulation and cAMP production were assayed in attached cells grown in 24-well-plates as described [28]. For cAMP synthesis measurements, [3H]-adenine (10 µCi/ml; GE Healthcare, UK) labeled control or treated cells were preincubated in DMEM containing 1 mM isobutylmethylxanthine for 15 min and then in the presence of increasing concentrations of carbachol for 10 min at 37 °C. The reaction was stopped by adding trichloroacetic acid (TCA) and cyclic [14C]-AMP (GE Healthcare, UK) that was used as recovery standard. Aliquots of TCA extracts were used for determination of TCA-soluble radioactivity and separation of [3H]-AMP from other labeled metabolites [16, 27]. TCA precipitates were dissolved in 1 M NaOH and used for determination of protein content.

For IPs accumulation, [3H]myo-inositol (10 µCi/ml; GE Healthcare, UK) labeled control or treated cells were preincubated in DMEM containing 12 mM LiCl for 15 min and then in the presence of increasing concentrations of carbachol for 10 min at 37 °C. The incubation was stopped on ice by adding TCA. Accumulated TCA-soluble radioactivity was used for estimation of formation of inositol phosphates without further separation [28]. TCA precipitates were dissolved in 1 M NaOH and aliquots of these lysates were used for scintillation counting for determination of radioactivity loading and protein content determination.

Activation of G-proteins by agonist reflects signal transduction across plasma membrane. Muscarinic receptor-induced activation of G-proteins was determined as an increase of GDP/GTP-γ35S binding to membranes induced by the muscarinic receptor agonist carbachol as described [17, 24]. Aliquots of membranes containing 5–20 µg protein were preincubated in 96-well-plate at 30 °C in binding buffer containing in addition 1 mM DTT, 1 µM GDP, and concentrations of carbachol ranging from 0 to 100 µM. Reaction was started by adding GTP-γ35S (Biotrend Chemikalien, Germany; SRA 1,000 Ci/µmol) to give a final concentration of 500 pM and incubation continued for another 20 min. Total content of G-proteins in membranes was determined as GTP-γ35S binding in the absence of GDP. Nonspecific binding was assessed in the presence of 10 µM unlabeled GTP. Incubation was terminated by rapid vacuum filtration through Whatman GF/F filters using Tomtec Harvester Mach III (USA). Radioactivity retained on filters was determined using solid scintillator Meltilex (Perkin Elmer, USA) as described for [3H]-NMS binding to membranes.

Data Evaluation

Curve fitting and statistical evaluation of data was done using Prism 6 (GraphPad Software Inc., CA, USA). Rectangular hyperbola was fitted to data obtained in saturation analysis experiments. A sigmoidal concentration–response curve equation with constant or variable slope as appropriate was fitted to data obtained in GTP-γ35S binding and cAMP synthesis experiments. A two-sites displacement curve equation was fitted to data obtained in displacement experiments. Better fits were determined using F test. The significance of differences among groups was tested by Anova and indicated post hoc test or t test as appropriate. Results are shown as mean ± SEM.

Results

We did not find differences between CHO-M1 and CHO-M3 cells in cell or membrane cholesterol concentration, either in control values or values after treatment with MBCD or Ch-MBCD. These values were therefore pooled (Table 1). Changes in cell and membrane cholesterol concentration were proportional.

Treatment of CHO-M1 and CHO-M3 cells with 10, 7.5, 5, 2.5 or 1.25 mM MBCD or with 0.25, 0.5, 1, 2 or 4 mM Ch-MBCD resulted in expected concentration-dependent changes in membrane cholesterol concentration (see legend to Fig. 1). Changes in membrane cholesterol content (control cells 225 nmol/mg protein) ranged from a decrease induced by 10 mM MBCD to 62 nmol/mg protein up to an increase to 768 nmol/mg protein induced by 4 mM Ch-MBCD. The decrease as well as the increase in membrane cholesterol content concentration-dependently attenuated the efficacy of carbachol in stimulating IPs accumulation in both CHO-M1 and CHO-M3 cells (Fig. 1a). In contrast, decreasing membrane cholesterol concentration dependently increased resting IPs accumulation in both cell lines while an increase in membrane cholesterol had no effect (Fig. 1b). Nevertheless, CHO-M1 cells were somehow more sensitive to changes in membrane cholesterol concentration with respect to both resting and carbachol-evoked accumulation of IPs.

A decrease in membrane cholesterol augmented (by 139 and 59 % for M1 and M3 receptors, respectively; p < 0.01 for both subtypes) while an increase in membrane cholesterol lowered (to 66 and 56 % for M1 and M3 receptors, respectively; p < 0.01 for both subtypes) binding of the muscarinic receptor antagonist 3H-NMS in both cell lines.
Table 1 Influence of changes in cholesterol concentration on 3H-N-methylscopolamine binding in intact CHO-M1 and CHO-M3 cells

| Treatment                  | MBBD (10 mM) | MBBD (5 mM) | Control | Ch-MBBD (2 mM) | Ch-MBBD (4 mM) |
|----------------------------|--------------|--------------|---------|----------------|----------------|
| Cell cholesterol (nmol/mg protein) | 13.1 ± 0.9   | 24.5 ± 1.1   | 51.8 ± 3.0 | 123.7 ± 11.9   | 178.5 ± 13.7   |
| (6)                        | (6)          | (6)          | (6)     | (6)            | (6)            |
| Membrane cholesterol (nmol/mg protein) | 61.6 ± 3.2   | 108.6 ± 5.5  | 212.2 ± 11.4 | 555.8 ± 38.5   | 745.7 ± 55.9   |
| (6)                        | (6)          | (6)          | (6)     | (6)            | (6)            |
| CHO-M1 cells               |              |              |         |                |                |
| Bmax (pmol/mg protein)     | 8.58 ± 0.30**| 5.97 ± 0.05**| 3.59 ± 0.06 | 3.12 ± 0.20    | 2.36 ± 0.22**  |
| (3)                       | (3)          | (3)          | (3)     | (3)            | (3)            |
| Kd (pM)                    | 454.7 ± 11.7*| 308.4 ± 6.4  | 259.1 ± 2.6 | 358.2 ± 60.4   | 370.8 ± 52.7   |
| (3)                       | (3)          | (3)          | (3)     | (3)            | (3)            |
| CHO-M3 cells               |              |              |         |                |                |
| Bmax (pmol/mg protein)     | 3.82 ± 0.14**| 3.20 ± 0.12**| 2.40 ± 0.11 | 2.22 ± 0.14    | 1.35 ± 0.20**  |
| (3)                       | (3)          | (3)          | (3)     | (3)            | (3)            |
| Kd (pM)                    | 289.4 ± 16.2 | 257.2 ± 8.9  | 244.5 ± 10.0 | 238.5 ± 6.9    | 396.5 ± 14.2** |
| (3)                       | (3)          | (3)          | (3)     | (3)            | (3)            |

Data are expressed as mean ± SEM of n experiments (in parentheses). Values for cholesterol concentrations were pooled because they did not differ between CHO-M1 and CHO-M3 cells and membranes. * p < 0.05; ** p < 0.01; significantly different from controls (middle column) by ANOVA followed by Dunnett’s multiple comparison test.

Fig. 1 Influence of membrane cholesterol concentration on efficacy of signal transduction in CHO-M1 and CHO-M3 cells. IPs accumulation in intact CHO cells expressing M1 (open squares) or M3 (closed squares) receptors induced by 100 μM carbachol was determined in cells pretreated with various concentrations of MBCD or cholesterol-saturated MBCD to decrease or increase membrane cholesterol content, respectively. Accumulation of IPs in the presence (a) or absence (b) of carbachol, expressed in percent of incorporated radioactivity (ordinate), is plotted against membrane cholesterol concentration (abscissa) determined after treatments. The cells were treated with 10–7.5–5–2.5–1.25 mM MBCD to reduce membrane cholesterol or with 0.25–0.5–1–2–4 mM Ch-MBCD to increase membrane cholesterol as described in “Methods” section. The corresponding averaged values of membrane cholesterol were 62, 82, 103, 146, 188, control 225, 251, 297, 344, 607, and 768 nmol/mg protein. Points are mean ± SEM of 3–4 experiments in triplicates. No treatment, control cells. **, p < 0.01 significantly different from control cells (dotted line) by ANOVA followed by Dunnett’s multiple comparison test.
The affinity of $^3$H-NMS binding was only marginally affected by membrane cholesterol manipulation but, surprisingly, differed between receptor subtypes. Maximal cholesterol depletion decreased the affinity of $^3$H-NMS binding in CHO-M1 cells (from 259 to 455 pM; $p < 0.05$) but had no effect in CHO-M3 cells. Conversely, maximal supplementation of cholesterol decreased the affinity of $^3$H-NMS binding in CHO-M3 cells (from 245 to 397 pM; $p < 0.01$) but had no effect in CHO-M1 cells.

Changes in membrane concentration of cholesterol in CHO-M1 cells also had only marginal effects on agonist binding. In competition experiments summarized in Table 2 we used carbachol that is a non-hydrolysable analog of natural agonist acetylcholine and $^3$H-NMS as a tracer. Maximal cholesterol depletion induced by 10 mM MBCD significantly decreased the affinity of agonist low affinity binding in CHO-M1 cells (from 168 to 330 μM; $p < 0.01$) but had no effect on the proportion or affinity of high affinity binding sites. In contrast, it has no effect on the binding parameters of carbachol in CHO-M3 cells as well as in CHO-M1 and CHO-M3 membranes. Similarly, membrane cholesterol supplementation had no effect on the parameters of carbachol binding in either CHO-M1 or CHO-M3 cells or analogous membranes.

In the next two sets of experiments we probed the effects of changing membrane cholesterol content in functional tests characteristics of signal transduction across cell membrane and activation of the intracellular signaling pathways mediated by $G_4$ G-proteins. First we tested carbachol-evoked stimulation of GTP-$\gamma^3S$ binding in membranes (Fig. 2). Total binding of GTP-$\gamma^3S$ (1 h incubation in the absence of GDP) that represents the level of activity of all available G-proteins incorporated in membranes did not differ between M1 and M3 membranes so the results were pooled (Table 3). Cholesterol depletion resulted in a small but significant increase of GTP-$\gamma^3S$ binding sites (by about 19%; $p < 0.01$) while cholesterol supplementation slightly decreased GTP-$\gamma^3S$ binding (by about 8%; $p < 0.05$). Resting binding of GTP-$\gamma^3S$ was significantly reduced in both CHO-M1 and CHO-M3 cholesterol-depleted membranes (by about 32 and 12 %, respectively; $p < 0.01$ for both subtypes) and slightly increased only in CHO-M1 cholesterol-supplemented membranes (by about 12%; $p < 0.05$). Concentration–response relationship of carbachol-induced stimulation of GTP-$\gamma^3S$ binding (Fig. 2) in CHO-M1 membranes was best fitted by a four-parameter equation (with Hill slope) while that for CHO-M3 membranes by a regular sigmoidal concentration–response curve (three-parameter equation). Neither cholesterol depletion nor cholesterol supplementation changed the shape of the concentration–response curves. Changes in cholesterol of CHO-M1 membranes did not influence either maximal response evoked by carbachol ($E_{max}$) or concentration of carbachol inducing half-maximal stimulation (EC$_{50}$). In contrast, both elevation and depletion of membrane cholesterol of CHO-M3 membranes significantly increased potency of carbachol ($p < 0.01$) but attenuated maximal response (Table 3). Changes in parameters of basal and carbachol-evoked cAMP synthesis in intact CHO-M1 and CHO-M3 cells after cholesterol modifying treatments were similar for both cell lines (Fig. 3, Table 4). Depletion of membrane cholesterol increased basal and carbachol-evoked cAMP synthesis (p < 0.05 for both subtypes) while supplementation of membrane cholesterol had no effect on basal synthesis of cAMP but reduced cAMP synthesis evoked by carbachol ($p < 0.05$ for both subtypes). None of the treatments influenced potency of carbachol.

### Discussion

The M1 muscarinic receptor is a major cerebral muscarinic receptor subtype that is essential for cognitive functions. Any malfunction of its $G_{q/11}$ G-protein-mediated signaling may thus adversely impact not only mental performance but also amyloid precursor protein processing and amyloid-$\beta$
We probed the influence of changing membrane cholesterol concentration on M1 and M3 receptor activation and signaling. Our results indicate that both an increase and a decrease in membrane cholesterol concentration-dependently attenuate maximal stimulation of preferential M1 and M3 receptor-mediated Gq/11 G-protein activation.

Table 3: Influence of changes in cholesterol concentration on carbachol-evoked GTP-γ35S in CHO-M1 and CHO-M3 membranes

| Treatment            | MBCD (10 mM) | MBCD (5 mM) | Control | Ch-MBCD (2 mM) | Ch-MBCD (4 mM) |
|----------------------|--------------|-------------|---------|----------------|----------------|
| **Pooled M1 and M3** |              |             |         |                |                |
| Total binding (ccpm/µg) | 5,310 ± 82** | 4,987 ± 56** | 4,469 ± 57 | 4,410 ± 63 | 4,127 ± 121* |
| (n)                  | (6)          | (4)         | (6)     | (4)            | (6)            |
| **M1 membranes**     |              |             |         |                |                |
| Basal binding (ccpm/µg) | 1,004 ± 46** | 997 ± 24**  | 1,473 ± 57 | 1,643 ± 32*  | 1,529 ± 30 |
| (n)                  | (3)          | (2)         | (3)     | (2)            | (3)            |
| Emax (ccpm/µg)       | 854 ± 31     | 857 ± 39    | 974 ± 11 | 810 ± 4       | 819 ± 81     |
| EC50 (µM)            | 42.5 ± 4.0   | 44.4 ± 11.8 | 64.6 ± 16.8 | 22.4 ± 0.9   | 18.5 ± 0.2   |
| Hill slope           | 0.708 ± 0.052| 0.745 ± 0.119| 0.720 ± 0.066 | 0.679 ± 0.009| 0.758 ± 0.059|
| (n)                  | (3)          | (2)         | (3)     | (2)            | (3)            |
| **M3 membranes**     |              |             |         |                |                |
| Basal binding (ccpm/µg) | 1,096 ± 30** | 1,172 ± 18  | 1,248 ± 27 | 1,333 ± 34   | 1,278 ± 17   |
| (n)                  | (3)          | (2)         | (3)     | (2)            | (3)            |
| Emax (ccpm/µg)       | 77.0 ± 11.0**| 118.5 ± 0.5**| 401 ± 30.8 | 341.5 ± 43.5 | 254.7 ± 18.9*|
| EC50 (µM)            | 2.7 ± 1.0**  | 3.1 ± 2.1** | 36.9 ± 2.6 | 6.6 ± 0.2**   | 9.3 ± 1.8**   |
| Hill slope           | 1            | 1           | 1       | 1              | 1              |
| (n)                  | (3)          | (2)         | (3)     | (2)            | (3)            |

Data are expressed as mean ± SEM of n experiments (in parentheses) in triplicates or quadruplicates. Values for GTP-γ35S binding are expressed in cpm/µg protein. Values for total binding in CHO-M1 and CHO-M3 membranes did not differ so they were pooled. *p < 0.05; **p < 0.01; significantly different from controls (middle column) by Anova followed by Dunnett’s multiple comparison test.
Moreover, depletion of membrane cholesterol has more pronounced effects than cholesterol supplementation on the efficacy of the agonist carbachol. This observation is in line with our preceding finding of reduced efficacy of carbachol-stimulated IPs accumulation in CHO-M1 cells induced by membrane cholesterol manipulation [28].

With respect to ligand binding, the major outcome of cholesterol depletion common for both cell lines was an increase in the density of antagonist binding sites in both cell lines that was accompanied with a small decrease in affinity (by 71%) only in CHO-M1 cells at the highest level of cholesterol reduction. Conversely, cholesterol supplementation decreased the density of binding sites at both cell lines only after the highest cholesterol supplementation with a small decrease in affinity (by 62%) only in CHO-M3 cells. We observed similar effects of cholesterol depletion in CHO-M2 cells [28] so that we assume that changes in receptor densities after membrane cholesterol manipulations are due to modifications in the accessibility of receptors to the antagonist ligand consequent to alterations of membrane physicochemical properties [11]. Unlike in CHO-M2 cells and membranes, we found no essential membrane cholesterol concentration-dependent changes in parameters of agonist binding in CHO-M1 and CHO-M3 cell lines or membranes prepared from treated cells. The differential pattern of changes in ligand binding characteristics among these three cell lines indicate that they are not an experimental artifact arising out of the treatment.

Table 4 Influence of changes in cholesterol concentration on carbachol-evoked cAMP synthesis in CHO-M1 and CHO-M3 cells

| Treatment               | MBCD (5 mM) | Control | Ch-MBCD (2 mM) |
|-------------------------|-------------|---------|----------------|
| **M1 cells**            |             |         |                |
| Basal synthesis (%)     | 0.97 ± 0.13** | 0.45 ± 0.02 | 0.40 ± 0.02    |
| Emax (%)                | 6.13 ± 0.32** | 2.09 ± 0.08 | 0.94 ± 0.07*   |
| EC50 (µM)               | 143 ± 23    | 146 ± 22 | 170 ± 29       |
| **M3 cells**            |             |         |                |
| Basal synthesis (%)     | 0.98 ± 0.12* | 0.59 ± 0.09 | 0.56 ± 0.04    |
| Emax (%)                | 2.95 ± 0.32** | 1.01 ± 0.03 | 0.25 ± 0.07*   |
| EC50 (µM)               | 124 ± 4     | 147 ± 27 | 110 ± 93       |

Data are expressed as mean ± SEM of three independent experiments in triplicates. Values for cAMP synthesis are expressed in percent of loaded radioactivity that did not differ among treatments. Pooled value of incorporated radioactivity was 216,550 ± 10,542 dpm/well (n = 18). * p < 0.05; ** p < 0.01; significantly different from controls (middle column) by Anova followed by Dunnett’s multiple comparison test.
Experiments aimed at determination of the effects of manipulation of membrane cholesterol on various elements of signal transduction yielded interesting results. There was no difference in total binding of GTP-γ35S (denoting G-protein concentration) between CHO-M1 and CHO-M3 (and also CHO-M2; not shown) membranes. Cholesterol depletion slightly augmented (by 18 %) while cholesterol supplementation slightly attenuated (by 8 %) total GTP-γ35S binding. We suppose that similar to antagonist binding, cholesterol concentration manipulations unmask or mask some GTP binding sites in membranes. In support of this view, western blot analysis of lysed membranes after cholesterol modifying treatment did not reveal any changes in the concentration of the major G-protein subclasses α-subunits indicating that the total protein concentration of α-subunits was not changed by the treatment [28]. Noteworthy, however, manipulation of cholesterol content may influence the stoichiometry of GTP interaction with G proteins. While the influence of cholesterol modifications on resting (in the absence of agonist) binding was basically similar in both CHO-M1 and CHO-M3 membranes, carbachol-stimulated GTP-γ35S binding markedly differed between them. Agonist-stimulated GTP-γ35S binding in control CHO-M1 membranes was best fitted by a sigmoidal curve with Hill slope less than unity that was not at all influenced by changes in membrane cholesterol concentration. In contrast, carbachol-stimulated GTP-γ35S binding in CHO-M3 membranes followed a three-parameter sigmoidal concentration–response curve. In addition, unlike in CHO-M1 cells, both cholesterol depletion and supplementation concentration-dependently reduced the maximal effect of carbachol but increased its potency. Together with the lack of effect on agonist binding these results provide evidence for alteration of M3 receptor-mediated Gs G-protein signaling also upstream of activated G-protein/effecter protein interaction.

Effects of changes in membrane cholesterol concentration exhibited different patterns on agonist-induced stimulation of the nonpreferential Gs G-protein signaling pathway than the pattern of overall G-protein activation or stimulation of the preferential phosphatidylinositol hydrolysis pathway. In both intact CHO-M1 and CHO-M3 cells, cholesterol depletion increased while cholesterol supplementation decreased carbachol-evoked cAMP synthesis. The sense of changes in muscarinic receptor stimulation-evoked metabolism of second messengers that result from alterations in membrane cholesterol concentration is basically the same in both cell lines. However, mechanisms of these changes differ in CHO-M1 and CHO-M3 cells. Results of binding experiments demonstrate that signal transmission across the membrane via the M1 receptor is not influenced by membrane cholesterol concentration. On the other hand, changes in membrane cholesterol concentration influence both agonist binding and G-protein activation in CHO-M3 cells. Together these data indicate that alterations in M1 receptor signaling as a results of changes in membrane cholesterol concentration are due to events downstream of receptor/G-protein activation while impact on M3 receptor signaling involves both components.

A role of cholesterol in the pathogenesis of Alzheimer’s disease remains a matter of controversy, in spite of the involvement of several research groups in such studies. Thus, considerable experimental evidence supporting both the beneficial and detrimental role of both increased and reduced cell cholesterol exists [25, 32, 36]. Most of experimental work has focused on mutual interactions of membrane cholesterol and constitutive cleavage of amyloid precursor protein and a role of β-amyloid in lipid metabolism [10]. It has been demonstrated that an increase in membrane cholesterol facilitates production of noxious β-amyloid fragments while reduction in membrane cholesterol has the opposite effect [7, 8, 34, 35, 38]. On the other hand, a decrease in membrane cholesterol concentration was detected in a subgroup of post mortem Alzheimer’s brains with reduced activity of the amyloid peptides degrading protease plasmin [23]. In other experiments, a small decrease in membrane cholesterol resulted in an increase in amyloid-β production while inhibition of amyloid-β production required a large decrease in cholesterol content [1]. Our results indicate that a relatively small drop in membrane cholesterol already results in highly significant attenuation in agonist-evoked Gq/11 G-protein-mediated M1 receptor signaling (Fig. 1: decrease by 35 %, p < 0.0001 by Anova and Dunnett’s test; decrease by 17 %, p < 0.027 by two-tailed t-test) that may attenuate β-secretase activity.

In summary, we demonstrate that changes in membrane cholesterol concentration markedly influence M1 and M3 muscarinic receptor-mediated signaling to the cell interior. Our data illustrate that changes in membrane cholesterol concentration have essentially no influence on M1 receptor/G-proteins interactions, suggesting that changes in signaling take place distal to this step. With regard to the preferential Gq/11 G-protein signaling pathway both increase and decrease in membrane cholesterol concentration results in concentration-dependent inhibition of accumulation of inositol phosphates. These effects are not due to a loss of phosphatidylinositol-specific phospholipase C because basal values (in the absence of agonist) are either not changed (high cholesterol) or increased (low cholesterol). Non-preferential agonist-stimulated Gs G-protein-mediated signaling differs from the inositol phosphates response. The decrease in membrane cholesterol concentration increases the cAMP response while increase in membrane cholesterol concentration inhibits the response. Taken together these results point to the activated G-protein/effecter protein interaction.
as the main site of action in the observed alterations of M1 receptor-mediated stimulation of second messenger pathways. These changes most likely depend on physicochemical properties of the membrane and changes in receptor localization and mobility within the membrane. On the other hand, alterations in agonist-stimulated GTP-γ35S binding in CHO-M3 membranes indicate that in case of the M3 receptor additional modification of liganded receptor/G-protein interaction may also play a role.

Acknowledgments This research was supported by projects EU FP7 project LipiDiDiet (Grant Agreement No 211696), RVO: 67985823, and grants GACR 14-05696S and P304/12/G069.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG (2004) Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167:953–960
2. Bonner TI (1989) The molecular basis of muscarinic receptor diversity. Trends Neurosci 12:148–151
3. Bonner TI (1989) New subtypes of muscarinic acetylcholine receptors. Trends Pharmacol Sci Suppl:11–15
4. Bonner TI, Buckley NJ, Young AC, Brann MR (1987) Identification of a family of muscarinic acetylcholine receptor genes. Science 237:527–532
5. Bonner TI, Young AC, Brann MR, Buckley NJ (1988) Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1:403–410
6. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, Greengard P (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/APP amyloid protein precursor. Proc Natl Acad Sci USA 89:10075–10078
7. Ebehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160:113–123
8. Fassbender K, Simons M, Bergmann C, Stroick M, Lotjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 40 and Abeta 42 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856–5861
9. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256–1272
10. Grimm MO, Grimm HS, Patzold AJ, Zinner EG, Halonen R, Duerer M, Tschape JA, De Strooper B, Muller U, Shen J, Hartmann T (2005) Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 7:118–1123
11. Head BP, Patel HH, Insel PA (2014) Interaction of membrane/lipid rafts with the cytoktoskeleton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim Biophys Acta 1838:532–545
12. Hu J, Wang Y, Zhang X, Lloyd IR, Li JH, Karpik J, Costanzis S, Wess J (2010) Structural basis of G protein-coupled receptor-G protein interactions. Nat Chem Biol 6:541–548
13. Hulme EC, Birdsell NJ, Buckley NJ (1990) Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol 30:633–673
14. Hulme EC, Kurtenbach E, Curtis CA (1991) Muscarinic acetylcholine receptors: structure and function. Biochem Soc Trans 19:133–138
15. Hulme EC, Lu ZL, Saldanha JW, Bee MS (2003) Structure and activation of muscarinic acetylcholine receptors. Biochem Soc Trans 31:29–34
16. Jakubik J, Bacakova L, Lisa V, el-Fakahany EE, Tucek S (1996) Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc Natl Acad Sci USA 93:8705–8709
17. Jakubik J, El-Fakahany EE, Dolezal V (2006) Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors. Mol Pharmacol 70:656–666
18. Jakubik J, Janickova H, El-Fakahany EE, Dolezal V (2011) Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy. Br J Pharmacol 162:1029–1044
19. Jakubik J, Janickova H, Randakova A, El-Fakahany EE, Dolezal V (2011) Subtype differences in pre-coupling of muscarinic acetylcholine receptors. PLoS ONE 6:e27732
20. Jones SV (1993) Muscarinic receptor subtypes: modulation of ion channels. Life Sci 52:457–464
21. Jones SV, Heilman CJ, Brann MR (1991) Functional responses of cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 40:242–247
22. Lander ES, Linton LM, Birren B et al (2001) Initial sequencing and analysis of the human genome. Nature 409:860–921
23. Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Delacourte A, Dingwall C, Dotti CG (2003) Raft disorganization leads to reduced plasmin activity in Alzheimer’s disease brains. EMBO Rep 4:1190–1196
24. Machova E, Jakubik J, Michal P, Oksman M, Ivonen H, Tanila H, Dolezal V (2008) Impairment of muscarinic transmission in transgenic APPswt/PS1dE9 mice. Neurobiol Aging 29:368–378
25. Maulik M, Westaway D, Jhamandas JH, Kar S (2013) Role of cholesterol in APP metabolism and its significance in Alzheimer’s disease pathogenesis. Mol Neurobiol 47:37–63
26. Michal P, El-Fakahany EE, Dolezal V (2007) Muscarinic M2 receptors directly activate Gq/11 and Gs G-proteins. J Pharmacol Exp Ther 320:607–614
27. Michal P, Lysikova M, Tucek S (2001) Dual effects of muscarinic M(2) acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists. Br J Pharmacol 132:1217–1228
28. Michal P, Rudajev V, El-Fakahany EE, Dolezal V (2009) Membrane cholesterol content influences binding properties of muscarinic M2 receptors and differentially impacts activation of second messenger pathways. Eur J Pharmacol 606:50–60
29. Nitsch RM (1996) From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer’s disease. Neurodegeneration 5:477–482
30. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304–307
31. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ (1987) Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 6:3923–3929
32. Reitz C (2013) Dyslipidemia and the risk of Alzheimer’s disease. Curr Atheroscler Rep 15:307
33. Santruckova E, Dolezal V, El-Fakahany EE, Jakubik J (2014) Differences in immediate and delayed responses of muscarinic acetylcholine receptor subtypes to brief exposure to xanomeline. PloS One (in press)

34. Simons K, Ehehalt R (2002) Cholesterol, lipid rafts, and disease. J Clin Invest 110:597–603

35. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95:6460–6464

36. Stefani M, Liguri G (2009) Cholesterol in Alzheimer’s disease: unresolved questions. Curr Alzheimer Res 6:15–29

37. Wess J, Blin N, Mutschler E, Blum K (1995) Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling. Life Sci 56:915–922

38. Yao J, Ho D, Calingasan NY, Pipalia NH, Lin MT, Beal MF (2012) Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. J Exp Med 209:2501–2513